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ohis issue of the Journal contains 2 papers that provide
nteresting insights from 2 large randomized lipid-lowering
rials that addressed relatively similar scientific questions. In
he PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis In Myo-
ardial Infarction 22) trial, investigators compared atorva-
tatin (80 mg) with pravastatin (40 mg) for patients ran-
omly assigned to treatment after an acute coronary
yndrome (ACS) (1). In the IDEAL (Incremental Decrease
n End Points Through Aggressive Lipid Lowering) trial
2), the 80-mg dosage of atorvastatin was compared with 20
o 40 mg of simvastatin in patients with a prior myocardial
nfarction (MI). Both studies were performed well and
ontributed significantly to the contemporary understanding
f the benefits of intensive reduction in cholesterol in
igh-risk secondary prevention patients. As a consequence
f these studies and others, the most recent update to the
ational Cholesterol Education Program recommends a
arget level of low-density lipoprotein cholesterol of 70
g/dl for high-risk patients (3).
See pages 2353 and 2358
Both studies pre-specified analysis of efficacy based upon
he time to first cardiovascular event, a time-honored
pproach for comparing survival curves for alternative inter-
entions. In such analyses, cardiovascular events occurring
ubsequent to the first event are ignored or “censored” and
herefore do not contribute to the statistical analysis. Now,
oth sets of investigators are reporting exploratory analyses
f these 2 trials using an alternative approach in which the
reviously censored events are included in the analysis (1,2).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cleveland Clinic Foundation, Cardiovascular Medicine, Cleveland,
hio. Dr. Nissen has received research support to perform clinical trials through the
leveland Clinic Coordinating Center for Clinical Research from Pfizer, Astra
eneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and
li Lilly. He consults for many pharmaceutical companies, but requires them tom
onate all honoraria or consulting fees directly to charity so that he receives neither
ncome nor a tax deduction.owever, there are important differences between the ap-
roaches used by the PROVE IT–TIMI 22 and IDEAL
nvestigators for their respective re-analyses. In the PROVE
T–TIMI 22 trial re-analysis, Murphy et al. (1) examined
xactly the same types of events included in the original
aper. In the IDEAL study re-analysis, Tikkanen et al. (2)
ought to examine a broader composite end point that
ncluded many additional categories of cardiovascular events
ot included in the original publication.
The rationale for these exploratory analyses is clearly
tated. As articulated by the 2 groups of investigators,
therosclerosis is a lifelong disease, and patients continue to
ace risks even after they suffer an initial cardiovascular
vent. Because the disease targeted by lipid-lowering ther-
py, atherosclerosis, is a pan-vascular process, involving
early every major blood vessel, the IDEAL study investi-
ators included end points not originally used as a compo-
ent of the primary efficacy analysis, such as stroke, hospi-
alization for unstable angina, revascularization or heart
ailure, and peripheral vascular disease. For both the
ROVE IT–TIMI 22 and IDEAL re-analyses, the inves-
igators had similar and worthy goals: to more fully describe
he effects of intensive lipid-lowering therapy on the total
urden of ischemic disease in cardiovascular patients.
The findings of these 2 re-analyses are interesting, although
erhaps not surprising. When additional events are considered,
he number of events prevented by more intensive lipid-
owering therapy was substantially greater. For the PROVE
T–TIMI 22 trial, the authors calculate a needed-to-treat
umber of 14, which is impressively small (1). Although not
alculated by the authors, the apparent needed-to-treat
umber for the IDEAL study using the broader definition
f morbidity-mortality events was also quite small (2); in
hat study, there was a 17% overall reduction in risk, and the
otal number of events was very large, namely, 4,295. Taken
ogether, these post-hoc analyses provide further support for
he “lower is better” concept in the management of low-
ensity lipoprotein cholesterol in high-risk patients.
Although these were post-hoc exploratory analyses, an
bvious question is whether such approaches should be used
ore commonly in prospective randomized clinical trials.
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Cardiovascular Outcomes in Randomized Trials December 15/22, 2009:2363–5here are 2 principal issues. First, should a broader com-
osite of morbid events be used in major cardiovascular
utcomes trials? Proponents of the use of broader end points
ontend that events such as hospitalization for unstable
ngina, heart failure, or revascularization represent impor-
ant adverse experiences for patients. Hospitalization and
nvasive procedures are unpleasant and result in considerable
nxiety, discomfort, and cost. Similarly, peripheral vascular
vents can induce suffering and markedly impair quality of
ife. If the goal of medical therapy is to relieve suffering, why
hould such events be routinely excluded from primary
fficacy analyses?
A further argument in favor of the use of broader end
oints is the contemporary reality that cardiovascular event
ates have decreased dramatically in recent years. In the
ROVE IT–TIMI 22 trial, 25% of patients suffered an
vent during 30 months of follow-up. However, with the
evelopment of better therapies, including intensive statin
dministration and dual antiplatelet therapy, clinical trials
nder design involving ACS patients postulate substantially
ower event rates. As a consequence of lower event rate
stimates, there has been a literal explosion in sample sizes
or more recent ACS or secondary prevention trials, now
requently approaching or exceeding 20,000 patients. The
osts of such studies are daunting and may now result in a
ailure of sponsors to be willing to expend the resources
ecessary to answer important scientific questions.
Despite these rationales for use of broader end points,
here are compelling counterarguments. So-called “hard”
utcomes such as death, MI, and stroke are irrevocable
vents with permanent consequences, whereas hospitaliza-
ion or revascularization may not have enduring conse-
uences. Indeed, some fraction of these “soft” events may be
onsidered “false alarms.” For example, in some patients
ospitalized for angina, the cardiac enzymes are never
levated, no procedures are undertaken, and the patient is
ischarged relatively promptly with no permanent conse-
uences. Patients admitted for congestive heart failure may
ctually have an exacerbation of chronic lung disease.
We must also consider the reliability of such end
oints. Most major outcomes trials are conducted glo-
ally, not infrequently including patients from industri-
lized nations in North America and Europe, but also
nvolving emerging or less developed countries in Asia,
astern Europe, and elsewhere. In such nations, the
ndications for hospitalization may differ greatly from
hose in North America or Europe. Indeed, even within
urope, different health care delivery models may result
n very divergent hospitalization rates for identical pre-
enting symptoms. Accordingly, the region of the world
ontributing the events can heavily influence interpreta-
ion of studies using soft end points.
There is also a major problem in adjudicating soft events.
ost modern trials rely upon centralized, blinded adjudi-
ation committees to review source material and determine
hether an investigator-reported event should be included in the final analysis. Hard events, such a MI or stroke, are
elatively easy to adjudicate. Source materials such as elec-
rocardiograms or computed tomography of the brain can be
bjectively evaluated, and the event classified relatively
eliably. However, for many of the soft events, adjudication
s difficult and inherently less reliable. Was a hospitalization
ruly caused by incident congestive heart failure or pneumo-
ia? Is the onset of “intermittent claudication” a correct or
ncorrect diagnosis in a patient with symptoms? In global
rials, the availability of source material may be compro-
ised by local standards of care. In the U.S., for example,
ngiography is more often employed in the diagnosis of
atients with suspected coronary ischemia. In Europe, and
articularly in developing countries, such resources are used
ore sparingly.
There remains another major risk in the application of
road cardiovascular end points. Not all therapies have an
qual effect on all types of adverse cardiovascular outcomes.
n infamous example comes from the diabetes literature in
he form of the PROACTIVE (Prospective Pioglitazone
linical Trial in Macrovascular Events) trial, which com-
ared pioglitazone to placebo for patients with type II
iabetes mellitus (4). The principal investigator was a
ascular surgeon, and therefore the study included events
uch as leg revascularization and amputation in the broad
omposite outcome. This composite end point failed to
chieve statistical significance (hazard ratio: 0.90, p 
.095). However, the hard end point of all-cause mortality,
I, and stroke showed a hazard ratio of 0.84 (p  0.027).
y including nonmodifiable events, the investigators missed
n opportunity to advance scientific understanding of the
ffects of a diabetes therapy.
Because of such concerns, a broad composite outcome
uch as the end points used in this re-analysis of the IDEAL
rial is not yet viewed as acceptable as a primary efficacy
easure for contemporary trials, particularly by the regula-
ory community. To my knowledge, the U.S. Food and
rug Administration has not granted approval or modified
he label of products on the basis of results of a trial using
n end point as broad as that employed in the IDEAL study
e-analysis. Such analyses are useful as secondary end points,
ut should not substitute for hard cardiovascular outcomes
s the primary efficacy measure.
What about using the totality of cardiovascular event,
ncluding all adverse cardiovascular outcomes, not just the
rst post-randomization event, as employed by the authors
n both of these papers (1,2)? Again, there are cogent
rguments in favor of such an approach, as nicely articulated
y both sets of authors. However, there are also compelling
ounterarguments. In coronary disease, the best predictor of
cardiovascular event is the temporal proximity of the
atient to a previous event. Stated another way, the event
ate after an ACS event is very high is the first few hours or
ays after the initial event, then declines gradually over the
ext 1 to 2 years. Accordingly, the patients who suffer annitial event in a clinical trial do not face a similar risk as
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December 15/22, 2009:2363–5 Cardiovascular Outcomes in Randomized Trialsatients who have not yet suffered a morbid event—their
isk is much higher. Accordingly, the apparent benefit of a
ore effective therapy is greatly magnified by counting
ubsequent events.
As a result of this phenomenon, counting recurrent
vents overemphasizes the contribution of a few patients
ho have an early event in a clinical trial. The conven-
ional approach, the time to first event, allows each
atient to contribute an equal weight to the analysis. All
atients can be considered as having an event or not
aving an event. However, when multiple events are
onsidered, patients with recurrent events begin to dom-
nate the analysis.
In summary, the findings reported in this issue of the
ournal by these 2 groups of investigators are useful and
ontribute to our understanding of the totality of the
enefits of intensive lipid-lowering therapy (1,2). In my
iew, however, they do not provide compelling evidence for
he use of such methods in prospectively designed trials.
he risks of overstating the benefits of any studied therapy
re considerable, and the reliability of efficacy analyses may
e compromised. Some adjustment in the use of the
hardest” end points (stroke, MI, and cardiovascular death)
ust be considered because of the explosion of sample size
n contemporary trials and the recognition that some soft
nd points contribute to the overall morbidity of this
isease. Hospitalization for unstable angina or revascular-
zation has been included as a component of the primary
fficacy measure in some recent trials and has generally
ielded reliable results. Nonetheless, the most objective
K
htandard remains time-to-event analysis for cardiovascular
eath, MI, and stroke.
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